drugset / Trial / NCT06816264

A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT06816264

Phase 2 Completed 120 enrolled Shandong Suncadia Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of HRS-5346 in adult participants with elevated Lp(a) at high risk for cardiovascular events.

Timeline

Start
2025-02-18
Primary completion
2025-09-29
Completion
2025-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-5346 Unknown Oral

Indications

No indication recorded.